These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 1995531

  • 21. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M.
    J Med Chem; 1995 May 12; 38(10):1786-92. PubMed ID: 7752202
    [Abstract] [Full Text] [Related]

  • 22. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: implications for extravascular transport and activity in tumors.
    Hicks KO, Siim BG, Pruijn FB, Wilson WR.
    Radiat Res; 2004 Jun 12; 161(6):656-66. PubMed ID: 15161354
    [Abstract] [Full Text] [Related]

  • 23. Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma.
    Yuan X, Tabassi K, Williams JA.
    Radiat Oncol Investig; 1999 Jun 12; 7(4):218-30. PubMed ID: 10492162
    [Abstract] [Full Text] [Related]

  • 24. Aerobic radiosensitization by SR 4233 in rodent and human cells: mechanistic and therapeutic implications.
    Zeman EM, Brown JM.
    Int J Radiat Biol; 1991 Jan 12; 59(1):117-31. PubMed ID: 1671059
    [Abstract] [Full Text] [Related]

  • 25. Alteration in the hypoxic fraction of quiescent cell populations by hyperthermia at mild temperatures.
    Masunaga S, Ono K, Suzuki M, Kinashi Y, Takagaki M, Akaboshi M.
    Int J Hyperthermia; 1997 Jan 12; 13(4):401-11. PubMed ID: 9278769
    [Abstract] [Full Text] [Related]

  • 26. Reoxygenation in the SCCVII tumor after KU-2285 sensitization plus single or fractionated irradiation.
    Shibamoto Y, Kitakabu Y, Murata R, Oya N, Shibata T, Sasai K, Takahashi M, Abe M.
    Int J Radiat Oncol Biol Phys; 1994 Jun 15; 29(3):583-6. PubMed ID: 8005819
    [Abstract] [Full Text] [Related]

  • 27. Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia.
    Blumenthal RD, Taylor A, Osorio L, Ochakovskaya R, Raleigh JA, Papadopoulou M, Bloomer WD, Goldenberg DM.
    Int J Cancer; 2001 Nov 15; 94(4):564-71. PubMed ID: 11745445
    [Abstract] [Full Text] [Related]

  • 28. Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation.
    McKeown SR, Friery OP, McIntyre IA, Hejmadi MV, Patterson LH, Hirst DG.
    Br J Cancer Suppl; 1996 Jul 15; 27():S39-42. PubMed ID: 8763843
    [Abstract] [Full Text] [Related]

  • 29. Hypoxia-inducible factor pathway inhibition resolves tumor hypoxia and improves local tumor control after single-dose irradiation.
    Helbig L, Koi L, Brüchner K, Gurtner K, Hess-Stumpp H, Unterschemmann K, Pruschy M, Baumann M, Yaromina A, Zips D.
    Int J Radiat Oncol Biol Phys; 2014 Jan 01; 88(1):159-66. PubMed ID: 24331663
    [Abstract] [Full Text] [Related]

  • 30. Lack of differential radiosensitization of hypoxic cells in a mouse tumor at low radiation doses per fraction by cisplatin.
    Sun JR, Brown JM.
    Radiat Res; 1993 Feb 01; 133(2):252-6. PubMed ID: 8438067
    [Abstract] [Full Text] [Related]

  • 31. Does tirapazamine (SR-4233) have any cytotoxic or sensitizing effect on three human tumour cell lines at clinically relevant partial oxygen pressure?
    Lartigau E, Guichard M.
    Int J Radiat Biol; 1995 Feb 01; 67(2):211-6. PubMed ID: 7884290
    [Abstract] [Full Text] [Related]

  • 32. Evaluation of hypoxic cell radio-sensitizers in terms of radio-sensitizing and repair-inhibiting potential. Dependency on p53 status of tumor cells and the effects on intratumor quiescent cells.
    Masunaga S, Uto Y, Nagasawa H, Hori H, Nagata K, Suzuki M, Kinashi Y, Ono K.
    Anticancer Res; 2006 Feb 01; 26(2A):1261-70. PubMed ID: 16619533
    [Abstract] [Full Text] [Related]

  • 33. Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors-reference to the effect on intratumor quiescent cells.
    Masunaga S, Ono K, Nishimura Y, Kanamori S, Saga T, Suzuki M, Kinashi Y, Takagaki M, Kasai S, Nagasawa H, Uto Y, Hori H.
    Int J Radiat Oncol Biol Phys; 2000 Jun 01; 47(3):799-807. PubMed ID: 10837967
    [Abstract] [Full Text] [Related]

  • 34. Early skin response to fractionated doses of pions for determining therapeutic gain factors.
    Ohizumi Y, Lam GK, Pickles T, Chaplin DJ.
    Tokai J Exp Clin Med; 1996 Jun 01; 21(2):69-75. PubMed ID: 9239808
    [Abstract] [Full Text] [Related]

  • 35. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines.
    Zölzer F, Streffer C.
    Int J Radiat Oncol Biol Phys; 2002 Nov 01; 54(3):910-20. PubMed ID: 12377345
    [Abstract] [Full Text] [Related]

  • 36. Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo.
    Yahiro T, Masui S, Kubota N, Yamada K, Kobayashi A, Kishii K.
    J Radiat Res; 2005 Sep 01; 46(3):363-72. PubMed ID: 16210793
    [Abstract] [Full Text] [Related]

  • 37. Hypoxia: new mechanisms for old?
    Adams GE.
    Int J Radiat Oncol Biol Phys; 1991 Mar 01; 20(3):643-4. PubMed ID: 1995555
    [No Abstract] [Full Text] [Related]

  • 38. Dependency of the effect of a vascular disrupting agent on sensitivity to tirapazamine and gamma-ray irradiation upon the timing of its administration and tumor size, with reference to the effect on intratumor quiescent cells.
    Masunaga S, Nagasawa H, Nagata K, Suzuki M, Uto Y, Hori H, Kinashi Y, Ono K.
    J Cancer Res Clin Oncol; 2007 Jan 01; 133(1):47-55. PubMed ID: 16924543
    [Abstract] [Full Text] [Related]

  • 39. Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.
    Shibata T, Shibamoto Y, Sasai K, Oya N, Murata R, Takagi T, Hiraoka M, Takahashi M, Abe M.
    Br J Cancer Suppl; 1996 Jul 01; 27():S61-4. PubMed ID: 8763848
    [Abstract] [Full Text] [Related]

  • 40. In vivo radiosensitizing activity of a new fluorinated hypoxic cell radiosensitizer, KU-2285, in combination with radiation dose fractionation.
    Sasai K, Fushiki M, Yukawa Y, Suyama S, Iwai H, Shibamoto Y, Nishimoto S, Takahashi M, Abe M.
    Int J Radiat Oncol Biol Phys; 1991 Oct 01; 21(5):1231-4. PubMed ID: 1938521
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.